The SEC has settled insider trading charges against Venar Ayar, Vincent Ayar and Johnathan Denha over trades made immediately before SERB Pharmaceuticals announced its acquisition of Y-mAbs Therapeutics, Inc. The enforcement action is notable because the alleged information chain extended beyond the company itself: confidential acquisition information moved from a SERB employee working on the transaction to his spouse, then to her law-firm partner, and ultimately to relatives who purchased Y-mAbs shares. The SEC says the stock closed 103.34% higher on the announcement day. Separate EDGAR transaction filings show why the information was highly market-sensitive: SERB agreed to pay $8.60 per share in cash, approximately a 105% premium to Y-mAbs' August 4, 2025 closing price, valuing the company at roughly $412 million.
U.S. Securities and Exchange Commission (SEC)
Official Release: https://www.sec.gov/enforcement-litigation/administrative-proceedings/34-106499-s
NEWS:
The SEC's September 25, 2026 orders trace the alleged information flow back to a SERB employee who was directly involved in the acquisition of Y-mAbs. According to the regulator, the employee told his spouse that SERB had finalized plans to acquire Y-mAbs and intended to announce the transaction the next day. His spouse then disclosed the information in confidence to her law-firm partner, Venar Ayar. The SEC found that Ayar passed the acquisition information to his brother, Vincent Ayar, and his cousin, Johnathan Denha, and encouraged them to purchase Y-mAbs shares. Vincent Ayar bought 1,847 shares on August 4, 2025, while Denha bought 6,200 shares; the SEC also says Denha caused another cousin to purchase Y-mAbs stock.
The underlying transaction helps explain the immediate market reaction. EDGAR filings show that SERB agreed to acquire all outstanding Y-mAbs shares for $8.60 per share in cash through a tender offer, representing approximately a 105% premium to the previous trading day's closing price and an equity value of about $412 million. The acquisition was strategically significant as well: Y-mAbs was a commercial-stage oncology company whose lead product, DANYELZA, is an FDA-approved therapy used in certain patients with relapsed or refractory high-risk neuroblastoma. SERB stated that the transaction would expand its rare-oncology portfolio and its U.S. presence. The acquisition was subsequently completed in September 2025.
Against that background, the trading pattern was economically straightforward for regulators to examine. On the day SERB publicly announced the acquisition, Y-mAbs shares closed 103.34% above the prior day's closing price. The SEC calculated profits of $7,831.25 for Vincent Ayar, $25,604.65 for Denha and $808.96 for another relative who traded after receiving the information. What distinguishes the case is that the alleged tipper at the center of the SEC action was not the original corporate insider and apparently did not need to trade personally for liability to arise. Instead, the enforcement record follows how material nonpublic information moved through professional and family relationships before reaching brokerage accounts.
Venar Ayar agreed to pay a civil penalty of $34,244.86. Vincent Ayar agreed to disgorge $7,831.25, pay $274.72 in prejudgment interest and a $7,831.25 civil penalty. Denha agreed to disgorge $25,604.65, pay $898.20 in prejudgment interest and a $26,413.61 civil penalty. The respondents settled without admitting the SEC's findings and consented to cease-and-desist orders. The SEC said the matter originated from its Market Abuse Unit's Analysis and Detection Center, which uses data analysis to identify suspicious trading patterns.
WHY THIS CASE MATTERS:
This case is a useful example of why merger-related insider trading investigations are not limited to executives, directors or employees who personally execute trades. A transaction can create a much wider confidentiality perimeter involving advisers, lawyers, employees' family members and other people who receive information through relationships of trust. Here, the SEC connected the timing of the purchases to a specific acquisition communication chain and then compared those trades with the abrupt repricing of Y-mAbs once the $8.60-per-share tender offer became public.
For investors, the case also shows why unusually profitable trading immediately before a takeover announcement can attract regulatory scrutiny even when the dollar amount is modest compared with major institutional insider-trading cases. The identifiable sequence of communications, the concentrated purchases one day before the announcement and the roughly 103% stock-price increase created a fact pattern that could be reconstructed using communications records, brokerage activity and market-surveillance data. The enforcement action therefore provides a clearer due-diligence lesson than a simple headline about insider trading: access to transaction information can create regulatory exposure several relationships removed from the original corporate source.
KEY POINTS:
- SERB Pharmaceuticals agreed to acquire Y-mAbs Therapeutics for approximately $412 million.
- The $8.60-per-share cash offer represented roughly a 105% premium to Y-mAbs' previous closing price.
- SEC orders describe confidential acquisition information moving through a SERB employee, spouse, law-firm partner and family members.
- Vincent Ayar purchased 1,847 shares and Johnathan Denha purchased 6,200 shares before the public announcement.
- Y-mAbs shares closed 103.34% higher on the acquisition-announcement day.
- The SEC identified more than $34,000 in combined profits among the traders described in the orders.
- The acquisition was later completed, adding Y-mAbs and DANYELZA to SERB's rare-oncology portfolio.
- The SEC said its Market Abuse Unit used data analysis to identify the suspicious trading activity.